Clinical trial
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
NCT04672460
Study timeline
Study start (actual)2020-12-21Date precision: day
Registry last updated2024-09-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorsunresolved
Solid Tumorsunresolved
Ovarian Cancerunresolved
Breast Cancerunresolved
Prostate Cancerunresolved
NSCLCunresolved
Pancreatic Cancerunresolved
Colorectal Cancerunresolved
Interventions
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
New YorkNew York, United States3PittsburghPennsylvania, United States3New HavenConnecticut, United States3Los AngelesCalifornia, United States2DallasTexas, United States1San AntonioTexas, United States1ClevelandOhio, United States1CincinnatiOhio, United States1The BronxNew York, United States1Kansas CityMissouri, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04672460 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.